First results of Russian COVID vaccine trial to include data from 5,000-10,000 people - developers

Interim results from Russia's late-stage human trial of a COVID-19 vaccine could include data from 5,000-10,000 participants, Denis Logunov, a director at the Gamaleya Institute that developed the vaccine, said on Monday.

The trial of the Sputnik V vaccine, involving 40,000 volunteers, has been under way in Moscow since the beginning of September. Interim results are expected to be published in November.

(This story has not been edited by Devdiscourse staff and is auto-generated from a syndicated feed.)